SG11201805253SA - Compositions and methods related to multimodal therapeutic cell systems for cancer indications - Google Patents
Compositions and methods related to multimodal therapeutic cell systems for cancer indicationsInfo
- Publication number
- SG11201805253SA SG11201805253SA SG11201805253SA SG11201805253SA SG11201805253SA SG 11201805253S A SG11201805253S A SG 11201805253SA SG 11201805253S A SG11201805253S A SG 11201805253SA SG 11201805253S A SG11201805253S A SG 11201805253SA SG 11201805253S A SG11201805253S A SG 11201805253SA
- Authority
- SG
- Singapore
- Prior art keywords
- massachusetts
- international
- cambridge
- rule
- methods related
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464424—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 July 2017 (20.07.2017) WIPOIPCT (10) International Publication Number WO 2017/123646 A1 (51) International Patent Classification: A61K35/12 (2015.01) CI2N 5/10 (2006.01) A61K35/18 (2015.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2017/013035 11 January 2017 (11.01.2017) English (30) Priority Data: 62/277,130 11 January 2016 (11.01.2016) 62/359,448 7 July 2016 (07.07.2016) 62/370,915 4 August 2016 (04.08.2016) 62/420,973 11 November 2016 (11.11.2016) English US US us us (71) Applicant: RUBIUS THERAPEUTICS, INC. [US/US]; 620 Memorial Dr #100W, Cambridge, Massachusetts 02139 (US). (72) Inventors: KAHVEJIAN, Avak; 1 Memorial Drive, 7th Floor, Cambridge, Massachusetts 02142 (US). MATA- FINK, Jordi; 8 Windsor Rd #1, Somerville, Massachusetts 02144 (US). DEANS, Robert, J.; 1609 Ramsgate Court, Riverside, California 92506 (US). CHEN, Tiffany, F.; 91 Sidney St. Apt 207, Cambridge, Massachusetts 02139 (US). ROUND, John; 1 Memorial Drive, 7th Floor, Cam bridge, Massachusetts 02142 (US). AFEYAN, Noubar, B.; 1 Sunset Ridge, Lexington, Massachusetts 02421 (US). STRAIGHT NISSEN, Torben; 68 Waban Hill Rd., Chestnut Hill, Massachusetts 02467 (US). DOWDEN, Nathan; 4 Goddu Ave., Winchester, Massachusetts 01890 (US). WICKHAM, Tom; 20 Hickory Lane, Groton, Mas sachusetts 1450 (US). ELLOUL, Sivan; 114 Eastbourne Rd., Newton, Massachusetts 02459 (US). (74) Agent: KOYFMAN, Hannah, R.; Lando & Anastasi, LLP, Riverfront Office Park, One Main Street, Suite 1100, Cambridge, Massachusetts 02142 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) V© •t m CJ o CJ (54) Title: COMPOSITIONS AND METHODS RELATED TO MULTIMODAL THERAPEUTIC CELL SYSTEMS FOR CAN CER INDICATIONS (57) : The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A mul timodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277130P | 2016-01-11 | 2016-01-11 | |
| US201662359448P | 2016-07-07 | 2016-07-07 | |
| US201662370915P | 2016-08-04 | 2016-08-04 | |
| US201662420973P | 2016-11-11 | 2016-11-11 | |
| PCT/US2017/013035 WO2017123646A1 (en) | 2016-01-11 | 2017-01-11 | Compositions and methods related to multimodal therapeutic cell systems for cancer indications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805253SA true SG11201805253SA (en) | 2018-07-30 |
Family
ID=57907000
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202007639SA SG10202007639SA (en) | 2016-01-11 | 2017-01-11 | Compositions and methods related to multimodal therapeutic cell systems for immune indications |
| SG11201805442XA SG11201805442XA (en) | 2016-01-11 | 2017-01-11 | Compositions and methods related to multimodal therapeutic cell systems for immune indications |
| SG11201805253SA SG11201805253SA (en) | 2016-01-11 | 2017-01-11 | Compositions and methods related to multimodal therapeutic cell systems for cancer indications |
| SG10201913837TA SG10201913837TA (en) | 2016-01-11 | 2017-01-11 | Compositions and methods related to multimodal therapeutic cell systems for cancer indications |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202007639SA SG10202007639SA (en) | 2016-01-11 | 2017-01-11 | Compositions and methods related to multimodal therapeutic cell systems for immune indications |
| SG11201805442XA SG11201805442XA (en) | 2016-01-11 | 2017-01-11 | Compositions and methods related to multimodal therapeutic cell systems for immune indications |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913837TA SG10201913837TA (en) | 2016-01-11 | 2017-01-11 | Compositions and methods related to multimodal therapeutic cell systems for cancer indications |
Country Status (22)
| Country | Link |
|---|---|
| US (8) | US10456421B2 (en) |
| EP (3) | EP3402491B1 (en) |
| JP (5) | JP2019501655A (en) |
| KR (2) | KR20180095713A (en) |
| CN (3) | CN108697733A (en) |
| AU (2) | AU2017207736A1 (en) |
| BR (2) | BR112018013853A2 (en) |
| CA (2) | CA3010510A1 (en) |
| DK (1) | DK3402491T3 (en) |
| ES (1) | ES2907695T3 (en) |
| HK (1) | HK1259079A1 (en) |
| HR (1) | HRP20220147T1 (en) |
| HU (1) | HUE057660T2 (en) |
| IL (2) | IL259991A (en) |
| LT (1) | LT3402491T (en) |
| MX (2) | MX2018008515A (en) |
| PL (1) | PL3402491T3 (en) |
| PT (1) | PT3402491T (en) |
| RS (1) | RS62939B1 (en) |
| SG (4) | SG10202007639SA (en) |
| SI (1) | SI3402491T1 (en) |
| WO (2) | WO2017123644A1 (en) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6219832B2 (en) | 2011-10-17 | 2017-10-25 | マサチューセッツ インスティテュート オブ テクノロジー | Intracellular delivery |
| AU2014306423B2 (en) | 2013-08-16 | 2019-04-18 | Massachusetts Institute Of Technology | Selective delivery of material to cells |
| EP3071515A2 (en) | 2013-11-18 | 2016-09-28 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| BR112016022814A8 (en) | 2014-04-01 | 2021-07-06 | Rubius Therapeutics Inc | pharmaceutical composition and its method of preparation, nucleic acid, and medical device or medical kit |
| KR20170074235A (en) | 2014-10-31 | 2017-06-29 | 메사추세츠 인스티튜트 오브 테크놀로지 | Delivery of biomolecules to immune cells |
| CN113897285A (en) | 2014-11-14 | 2022-01-07 | 麻省理工学院 | Disruption and field-effected delivery of compounds and compositions into cells |
| US11125739B2 (en) | 2015-01-12 | 2021-09-21 | Massachusetts Institute Of Technology | Gene editing through microfluidic delivery |
| CA2988996A1 (en) | 2015-07-09 | 2017-01-12 | Massachusetts Institute Of Technology | Delivery of materials to anucleate cells |
| EP3344575B1 (en) | 2015-09-04 | 2020-04-15 | SQZ Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
| AU2017207736A1 (en) | 2016-01-11 | 2018-07-12 | Rubius Therapeutics, Inc. | Compositions and methods related to multimodal therapeutic cell systems for immune indications |
| US11020435B2 (en) | 2017-02-17 | 2021-06-01 | Rubius Therapeutics, Inc. | Functionalized erythroid cells |
| US20210228738A1 (en) * | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| JP2020530454A (en) | 2017-08-07 | 2020-10-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Platform for producing safe cell therapies |
| US10960071B2 (en) | 2017-08-07 | 2021-03-30 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| AU2018328283A1 (en) * | 2017-09-07 | 2020-02-20 | Cue Biopharma, Inc. | Antigen-presenting polypeptides and methods of use thereof |
| CN111655292A (en) * | 2017-12-07 | 2020-09-11 | 旗舰先锋创新V股份有限公司 | Cellular biologicals and therapeutic uses thereof |
| KR20200104887A (en) * | 2017-12-23 | 2020-09-04 | 루비우스 테라퓨틱스, 아이엔씨. | Artificial antigen presenting cells and methods of use |
| RU2020132924A (en) * | 2018-03-08 | 2022-04-11 | Рубиус Терапьютикс, Инк. | THERAPEUTIC CELL SYSTEMS AND METHODS FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES |
| KR20210024488A (en) * | 2018-05-24 | 2021-03-05 | 러쉬 유니버시티 메디컬 센터 | ICOSL for use as a kidney treatment |
| US11166996B2 (en) | 2018-12-12 | 2021-11-09 | Flagship Pioneering Innovations V, Inc. | Anellovirus compositions and methods of use |
| CN113795580A (en) | 2019-01-18 | 2021-12-14 | 旗舰创业股份有限公司 | TREM compositions and uses thereof |
| BR112021016451A2 (en) * | 2019-02-20 | 2021-11-09 | Rubius Therapeutics Inc | Engineered erythroid cell including chargeable antigen-presenting polypeptides and methods of use |
| WO2020181013A1 (en) | 2019-03-04 | 2020-09-10 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides and pharmaceutical compositions thereof |
| US20200299369A1 (en) * | 2019-03-18 | 2020-09-24 | Bio-Rad Abd Serotec Gmbh | Antigen binding fragments conjugated to a plurality of fc isotypes and subclasses |
| WO2020198403A2 (en) | 2019-03-25 | 2020-10-01 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising modified circular polyribonucleotides and uses thereof |
| EP3963092A1 (en) * | 2019-05-02 | 2022-03-09 | Predictive Technology Group, Inc. | Somatic cancer driver mutations in endometriosis lesions contribute to secondary cancer risk |
| CN114269921A (en) | 2019-05-31 | 2022-04-01 | 旗舰创业股份有限公司 | Use of TREM compositions to modulate tRNA cells |
| WO2020252436A1 (en) | 2019-06-14 | 2020-12-17 | Flagship Pioneering Innovations Vi, Llc | Circular rnas for cellular therapy |
| US20220305128A1 (en) | 2019-06-19 | 2022-09-29 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides for protein modulation and uses thereof |
| CN112195154B (en) * | 2019-07-08 | 2024-03-29 | 江苏汇智生物科技有限公司 | Cell for genetically modifying and expressing modified PLA2R receptor and application thereof |
| EP4025048A2 (en) | 2019-09-05 | 2022-07-13 | Hemanext Inc. | Methods for the preservation of reagent red blood cells using carbon monoxide |
| WO2021073613A1 (en) * | 2019-10-18 | 2021-04-22 | Westlake Therapeutics (Hangzhou) Co. Limited | Engineered red blood cells presenting specific cancer neoantigen with artificial mhc |
| EP4055169A1 (en) | 2019-11-04 | 2022-09-14 | Flagship Pioneering, Inc. | Methods of modifying a nucleic acid sequence |
| US20220364092A1 (en) | 2019-11-04 | 2022-11-17 | Flagship Pioneering, Inc. | Trem compositions for con-rare codons and related uses |
| WO2021155177A1 (en) | 2020-01-29 | 2021-08-05 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising linear polyribonucleotides for protein modulation and uses thereof |
| WO2021155175A1 (en) | 2020-01-29 | 2021-08-05 | Flagship Pioneering Innovations Vi, Llc | Compositions for translation and methods of use thereof |
| WO2021155171A1 (en) | 2020-01-29 | 2021-08-05 | Flagship Pioneering Innovations Vi, Llc | Delivery of compositions comprising circular polyribonucleotides |
| CN115397395A (en) * | 2020-02-07 | 2022-11-25 | 加利福尼亚大学董事会 | Methods and uses for bioengineering enucleated cells |
| US20230203192A1 (en) | 2020-05-20 | 2023-06-29 | Flagship Pioneering, Inc. | Compositions and methods for producing human polyclonal antibodies |
| US20230193311A1 (en) | 2020-05-20 | 2023-06-22 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
| TW202206097A (en) | 2020-05-20 | 2022-02-16 | 美商旗艦先鋒創新有限責任公司 | Coronavirus antigen compositions and their uses |
| US20230203509A1 (en) | 2020-05-29 | 2023-06-29 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods relating thereto |
| MX2022015042A (en) | 2020-05-29 | 2023-03-09 | Flagship Pioneering Innovations Vi Llc | Trem compositions and methods relating thereto. |
| WO2021262799A1 (en) | 2020-06-23 | 2021-12-30 | Flagship Pioneering, Inc. | Anti-viral compounds and methods of using same |
| IL300947A (en) | 2020-09-03 | 2023-04-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions and uses thereof |
| CA3206285A1 (en) | 2020-12-23 | 2022-06-30 | Flagship Pioneering, Inc. | Compositions of modified trems and uses thereof |
| TW202241471A (en) | 2021-01-08 | 2022-11-01 | 美商盧比亞斯治療公司 | Methods of increasing nkp30-positive lymphocytes in a subject and uses thereof |
| CA3208619A1 (en) * | 2021-02-26 | 2022-09-01 | Cytonus Therapeutics, Inc. | Compositions and methods for therapeutic delivery |
| TW202304482A (en) | 2021-03-14 | 2023-02-01 | 美商盧比亞斯治療公司 | Methods of increasing nkg2d-positive lymphocytes in a subject and uses thereof |
| AU2022246895A1 (en) | 2021-03-31 | 2023-10-19 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| WO2023009547A1 (en) | 2021-07-26 | 2023-02-02 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and uses thereof |
| TW202330916A (en) | 2021-09-17 | 2023-08-01 | 美商旗艦先鋒創新有限責任公司 | Compositions and methods for producing circular polyribonucleotides |
| CA3234817A1 (en) * | 2021-10-12 | 2023-04-20 | Remo MOOMIAIE | Systems and methods for manufacturing of therapeutic cells |
| WO2023069397A1 (en) | 2021-10-18 | 2023-04-27 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
| CA3238735A1 (en) | 2021-11-24 | 2023-06-01 | Jennifer A. Nelson | Immunogenic compositions and their uses |
| CA3239266A1 (en) | 2021-11-24 | 2023-06-01 | Flagship Pioneering Innovations Vi, Llc | Coronavirus immunogen compositions and their uses |
| AU2022397292A1 (en) | 2021-11-24 | 2024-05-30 | Flagship Pioneering Innovations Vi, Llc | Varicella-zoster virus immunogen compositions and their uses |
| AU2022417517A1 (en) | 2021-12-22 | 2024-06-27 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
| CA3241026A1 (en) | 2021-12-23 | 2023-06-29 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides encoding antifusogenic polypeptides |
| WO2023220083A1 (en) | 2022-05-09 | 2023-11-16 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods of use for treating proliferative disorders |
| TW202409283A (en) | 2022-05-13 | 2024-03-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | Double stranded dna compositions and related methods |
| WO2023230549A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulation of tumor suppressors and oncogenes |
| WO2023230573A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulation of immune responses |
| WO2023230566A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating cytokines |
| WO2023230578A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating circulating factors |
| WO2023230570A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating genetic drivers |
| WO2023250112A1 (en) | 2022-06-22 | 2023-12-28 | Flagship Pioneering Innovations Vi, Llc | Compositions of modified trems and uses thereof |
| WO2024059740A1 (en) * | 2022-09-14 | 2024-03-21 | Synthego Corporation | Genetically modified polynucleotides and cells expressing modified mhc proteins and uses thereof |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
| WO2024097664A1 (en) | 2022-10-31 | 2024-05-10 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
| WO2024102799A1 (en) | 2022-11-08 | 2024-05-16 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for producing circular polyribonucleotides |
| WO2024129988A1 (en) | 2022-12-14 | 2024-06-20 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for delivery of therapeutic agents to bone |
| US20240238473A1 (en) | 2023-01-09 | 2024-07-18 | Beth Israel Deaconess Medical Center, Inc. | Recombinant nucleic acid molecules and their use in wound healing |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| WO2024151685A1 (en) | 2023-01-09 | 2024-07-18 | Beth Israel Deaconess Medical Center, Inc. | Recombinant nucleic acid molecules and their use in wound healing |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5674704A (en) * | 1993-05-07 | 1997-10-07 | Immunex Corporation | Cytokine designated 4-IBB ligand |
| EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US20020151004A1 (en) * | 2000-07-24 | 2002-10-17 | Roger Craig | Delivery vehicles and methods for using the same |
| CA2418835A1 (en) | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| WO2004087876A2 (en) * | 2003-03-25 | 2004-10-14 | Valeocyte Therapies Llc | Use of red blood cells to facilitate cell activation |
| DE10335833A1 (en) * | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfection of blood cells with mRNA for immune stimulation and gene therapy |
| FR2873925B1 (en) | 2004-08-05 | 2006-10-13 | Erytech Pharma Soc Par Actions | METHOD AND DEVICE FOR LYSE-RESCALING FOR THE INCORPORATION OF ACTIVE PRINCIPLE, IN PARTICULAR ASPARAGINASE OR INOSITOL HEXAPHOSPHATE, IN ERYTHROCYTES |
| FR2884717B1 (en) | 2005-04-25 | 2009-07-03 | Erytech Pharma Soc Par Actions | ERYTHROCYTES CONTAINING ARGININE DEIMINASE |
| JP5236461B2 (en) | 2005-05-17 | 2013-07-17 | ユニバーシティ オブ コネチカット | Compositions and methods for immunomodulation in organisms |
| WO2007030708A2 (en) | 2005-09-08 | 2007-03-15 | Adnexus Therapeutics, Inc. | Antimicrobial adzymes and uses thereof |
| US7462485B2 (en) | 2005-10-07 | 2008-12-09 | Glaser Lawrence F | Modified erythrocytes and uses thereof |
| FR2919804B1 (en) | 2007-08-08 | 2010-08-27 | Erytech Pharma | COMPOSITION AND ANTI-TUMOR THERAPEUTIC VACCINE |
| FR2925339B1 (en) | 2007-12-24 | 2010-03-05 | Erytech Pharma | DRUG FOR THE TREATMENT OF PANCREATIC CANCER |
| US20100316620A1 (en) | 2008-02-13 | 2010-12-16 | Vanessa Bourgeaux | Formulation and Method for the Prevention and Treatment of Skeletal Manifestation of Gaucher's Disease |
| FR2928270B1 (en) | 2008-03-10 | 2011-01-21 | Erytech Pharma | FORMULATION METHOD FOR THE PREVENTION OR TREATMENT OF BONE METASTASES AND OTHER BONE DISEASES |
| US8211656B2 (en) * | 2008-08-13 | 2012-07-03 | The Invention Science Fund I, Llc | Biological targeting compositions and methods of using the same |
| FR2938332B1 (en) | 2008-11-07 | 2011-11-25 | Erytech Pharma | PREDICTIVE TEST FOR NEUTRALIZATION OF ASPARAGINASE ACTIVITY |
| FR2944106B1 (en) | 2009-04-03 | 2012-09-28 | Erytech Pharma | METHOD OF DETERMINING INOSITOL HEXAPHOSPHATE (IHP). |
| EP2493487B1 (en) | 2009-10-27 | 2016-08-24 | Erytech Pharma | Composition to induce specific immune tolerance |
| CA2807942C (en) * | 2010-08-10 | 2021-07-27 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
| EP2825048A4 (en) | 2012-03-13 | 2015-10-14 | Anthrogenesis Corp | Modified erythrocyte precursor cells and uses thereof |
| KR20140145148A (en) | 2012-03-21 | 2014-12-22 | 에리테끄 파르마 | Medicament for the treatment of acute myeloid leukemia (AML) |
| CN103224957B (en) | 2013-04-16 | 2017-08-04 | 福建三一造血技术有限公司 | The method of external evoked generation ASPase containing L II red blood cell medicine |
| FR3005420B1 (en) | 2013-05-07 | 2015-09-18 | Erytech Pharma | METHOD OF STABILIZING SUSPENSIONS OF ERYTHROCYTES ENCAPSULATING AN ACTIVE INGREDIENT, SUSPENSIONS OBTAINED |
| US10260038B2 (en) | 2013-05-10 | 2019-04-16 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| AU2014262474B2 (en) | 2013-05-10 | 2019-10-31 | Whitehead Institute For Biomedical Research | In vitro production of red blood cells with sortaggable proteins |
| EP2813234A1 (en) | 2013-06-11 | 2014-12-17 | Erytech Pharma | Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof |
| EP3071515A2 (en) | 2013-11-18 | 2016-09-28 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| FR3017299B1 (en) | 2014-02-12 | 2018-05-18 | Erytech Pharma | PHARMACEUTICAL COMPOSITION COMPRISING ERYTHROCYTES ENCAPSULATING A PLP ENZYME AND ITS COFACTOR |
| BR112016022814A8 (en) | 2014-04-01 | 2021-07-06 | Rubius Therapeutics Inc | pharmaceutical composition and its method of preparation, nucleic acid, and medical device or medical kit |
| US20180135012A1 (en) | 2015-05-13 | 2018-05-17 | Rubius Therapeutics, Inc. | Membrane-receiver complex therapeutics |
| EP3187190A1 (en) | 2015-12-31 | 2017-07-05 | Erytech Pharma | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion |
| AU2017207736A1 (en) | 2016-01-11 | 2018-07-12 | Rubius Therapeutics, Inc. | Compositions and methods related to multimodal therapeutic cell systems for immune indications |
| EP3481943A1 (en) | 2016-07-07 | 2019-05-15 | Rubius Therapeutics, Inc. | Compositions and methods related to therapeutic cell systems expressing exogenous rna |
| CN110225756A (en) | 2016-12-02 | 2019-09-10 | 鲁比厄斯治疗法股份有限公司 | Composition relevant to the cell system for penetrating solid tumor and method |
| US11020435B2 (en) | 2017-02-17 | 2021-06-01 | Rubius Therapeutics, Inc. | Functionalized erythroid cells |
| US20190062788A1 (en) | 2017-08-22 | 2019-02-28 | Rubius Therapeutics, Inc. | Lipid nanoparticle methods and compositions for producing engineered erythroid cells |
| WO2019090148A2 (en) | 2017-11-03 | 2019-05-09 | Rubius Therapeutics, Inc. | Compositions and methods related to therapeutic cell systems for tumor growth inhibition |
| WO2019133881A1 (en) | 2017-12-29 | 2019-07-04 | Rubius Therapeutics, Inc. | Gene editing and targeted transcriptional modulation for enginerering erythroid cells |
-
2017
- 2017-01-11 AU AU2017207736A patent/AU2017207736A1/en not_active Abandoned
- 2017-01-11 LT LTEPPCT/US2017/013035T patent/LT3402491T/en unknown
- 2017-01-11 JP JP2018535851A patent/JP2019501655A/en active Pending
- 2017-01-11 KR KR1020187022906A patent/KR20180095713A/en unknown
- 2017-01-11 CN CN201780006113.4A patent/CN108697733A/en active Pending
- 2017-01-11 BR BR112018013853A patent/BR112018013853A2/en not_active Application Discontinuation
- 2017-01-11 KR KR1020187022922A patent/KR20180095098A/en unknown
- 2017-01-11 WO PCT/US2017/013033 patent/WO2017123644A1/en active Application Filing
- 2017-01-11 WO PCT/US2017/013035 patent/WO2017123646A1/en active Application Filing
- 2017-01-11 MX MX2018008515A patent/MX2018008515A/en unknown
- 2017-01-11 CA CA3010510A patent/CA3010510A1/en active Pending
- 2017-01-11 SG SG10202007639SA patent/SG10202007639SA/en unknown
- 2017-01-11 SI SI201731074T patent/SI3402491T1/en unknown
- 2017-01-11 SG SG11201805442XA patent/SG11201805442XA/en unknown
- 2017-01-11 PT PT177017761T patent/PT3402491T/en unknown
- 2017-01-11 PL PL17701776T patent/PL3402491T3/en unknown
- 2017-01-11 CN CN201780006086.0A patent/CN108778298A/en active Pending
- 2017-01-11 CN CN202211081626.0A patent/CN115969987A/en not_active Withdrawn
- 2017-01-11 EP EP17701776.1A patent/EP3402491B1/en active Active
- 2017-01-11 SG SG11201805253SA patent/SG11201805253SA/en unknown
- 2017-01-11 HU HUE17701776A patent/HUE057660T2/en unknown
- 2017-01-11 CA CA3009063A patent/CA3009063A1/en active Pending
- 2017-01-11 SG SG10201913837TA patent/SG10201913837TA/en unknown
- 2017-01-11 MX MX2018008514A patent/MX2018008514A/en unknown
- 2017-01-11 AU AU2017207738A patent/AU2017207738A1/en not_active Abandoned
- 2017-01-11 EP EP21216483.4A patent/EP4019026A1/en not_active Withdrawn
- 2017-01-11 RS RS20220172A patent/RS62939B1/en unknown
- 2017-01-11 HR HRP20220147TT patent/HRP20220147T1/en unknown
- 2017-01-11 DK DK17701776.1T patent/DK3402491T3/en active
- 2017-01-11 ES ES17701776T patent/ES2907695T3/en active Active
- 2017-01-11 JP JP2018535844A patent/JP7093302B2/en active Active
- 2017-01-11 EP EP17703498.0A patent/EP3402492B1/en active Active
- 2017-01-11 BR BR112018013728A patent/BR112018013728A2/en not_active Application Discontinuation
- 2017-09-26 US US15/716,141 patent/US10456421B2/en not_active Expired - Fee Related
-
2018
- 2018-02-26 US US15/905,445 patent/US20180187155A1/en not_active Abandoned
- 2018-02-27 US US15/906,873 patent/US10568910B2/en not_active Expired - Fee Related
- 2018-06-13 IL IL259991A patent/IL259991A/en unknown
- 2018-06-13 IL IL260010A patent/IL260010A/en unknown
- 2018-12-03 US US16/207,568 patent/US10716811B2/en active Active
-
2019
- 2019-01-29 HK HK19101579.6A patent/HK1259079A1/en unknown
- 2019-09-18 US US16/574,830 patent/US10517897B1/en not_active Expired - Fee Related
-
2020
- 2020-01-08 US US16/737,661 patent/US20200129556A1/en not_active Abandoned
-
2021
- 2021-03-01 JP JP2021031998A patent/JP2021078519A/en active Pending
- 2021-05-13 JP JP2021081727A patent/JP2021112216A/en active Pending
- 2021-11-17 US US17/528,422 patent/US20220072048A1/en active Pending
-
2022
- 2022-09-16 JP JP2022148073A patent/JP2022171843A/en not_active Withdrawn
-
2023
- 2023-01-25 US US18/159,229 patent/US20230293588A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805253SA (en) | Compositions and methods related to multimodal therapeutic cell systems for cancer indications | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201803728YA (en) | Topical pharmaceutical formulations for treating inflammatory-related conditions | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201805784PA (en) | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases | |
| SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
| SG11201804787UA (en) | Human immunodeficiency virus neutralizing antibodies | |
| SG11201807187XA (en) | Binding members to pd-l1 | |
| SG11201906223TA (en) | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer | |
| SG11201900468YA (en) | Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201811152YA (en) | Uses of extracellular vesicle comprising a fusion protein having fc binding capacity | |
| SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
| SG11201809522WA (en) | Method of nucleic acid sequence determination | |
| SG11201804134YA (en) | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment | |
| SG11201807286WA (en) | Methods and compositions for transducing lymphocytes and regulated expansion thereof | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201805136TA (en) | Group b adenovirus encoding an anti-tcr-complex antibody or fragment | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201900200XA (en) | Tgfb antibodies, methods, and uses | |
| SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| SG11201811150WA (en) | Ev-mediated delivery of binding protein-small molecule conjugates | |
| SG11201805420SA (en) | Antibodies and conjugates thereof | |
| SG11201807780XA (en) | Customizable facility |